A novel, high-efficiency cellular model of fibrillar α-synuclein inclusions and the examination of mutations that inhibit amyloid formation

Journal of Neurochemistry

Volumn 113, Issue 2, 2010, Pages 374-388

  Waxman, Elisa A ^a   Giasson, Benoit I ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

synuclein; Cellular model; Fibrillization; Inhibitors; Nucleation; Parkinson's disease; Phosphorylation

Indexed keywords

ALPHA SYNUCLEIN; AMYLOID; CALCIUM PHOSPHATE; THIOFLAVINE;

ARTICLE; CELL AGGREGATION; CELL CULTURE; GENE; GENETIC TRANSFECTION; NEUROBLASTOMA; POINT MUTATION; PRIORITY JOURNAL; T72P GENE; T75P GENE; UBIQUITINATION; V66P GENE;

ALPHA-SYNUCLEIN; AMYLOID; CALCIUM PHOSPHATES; CELL LINE, TRANSFORMED; HUMANS; HYDROPHOBICITY; INCLUSION BODIES; POINT MUTATION; THIAZOLES; TRANSFECTION;

EID: 77949706598     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/j.1471-4159.2010.06592.x     Document Type: Article

References (71)

1. Ahn K. J., Paik S. R., Chung K. C. Kim J. (2006) Amino acid sequence motifs and mechanistic features of the membrane translocation of alpha-synuclein. J. Neurochem. 97, 265 279.
2. Anderson J. P., Walker D. E., Goldstein J. M. et al. (2006) Phosphorylation of Ser-129 is the dominant pathological modification of alpha-synuclein in familial and sporadic Lewy body disease. J. Biol. Chem. 281, 29739 29752.
3. Ardley H. C., Scott G. B., Rose S. A., Tan N. G. Robinson P. A. (2004) UCH-L1 aggresome formation in response to proteasome impairment indicates a role in inclusion formation in Parkinson's disease. J. Neurochem. 90, 379 391.
4. Biere A. L., Wood S. J., Wypych J. et al. (2000) Parkinson's disease-associated alpha-synuclein is more fibrillogenic than β- and γ-synuclein and cannot cross-seed its homologs. J. Biol. Chem. 275, 34574 34579.
5. Bisaglia M., Schievano E., Caporale A., Peggion E. Mammi S. (2006) The 11-mer repeats of human alpha-synuclein in vesicle interactions and lipid composition discrimination: a cooperative role. Biopolymers 84, 310 316.
6. von Bohlen Und H. O. (2004) Synucleins and their relationship to Parkinson's disease. Cell Tissue Res. 318, 163 174.
7. Conway K. A., Harper J. D. Lansbury P. T. (1998) Accelerated in vitro fibril formation by a mutant alpha-synuclein linked to early-onset Parkinson disease. Nat. Med. 4, 1318 1320.
8. Conway K. A., Harper J. D. Lansbury P. T. (2000) Fibrils formed in vitro from alpha-synuclein and two mutant forms linked to Parkinson's disease are typical amyloid. Biochemistry 39, 2552 2563.
9. Crystal A. S., Giasson B. I., Crowe A., Kung M. P., Zhuang Z. P., Trojanowski J. Q. Lee V. M. (2003) A comparison of amyloid fibrillogenesis using the novel fluorescent compound K114. J. Neurochem. 86, 1359 1368.
10. Desplats P., Lee H. J., Bae E. J., Patrick C., Rockenstein E., Crews L., Spencer B., Masliah E. Lee S. J. (2009) Inclusion formation and neuronal cell death through neuron-to-neuron transmission of alpha-synuclein. Proc. Natl Acad. Sci. U S A 106, 13010 13015.
11. Du H. N., Tang L., Luo X. Y., Li H. T., Hu J., Zhou J. W. Hu H. Y. (2003) A peptide motif consisting of glycine, alanine, and valine is required for the fibrillization and cytotoxicity of human alpha-synuclein. Biochemistry 42, 8870 8878.
12. Duda J. E., Giasson B. I., Gur T. L. et al. (2000) Immunohistochemical and biochemical studies demonstrate a distinct profile of alpha-synuclein permutations in multiple system atrophy. J. Neuropathol. Exp. Neurol. 59, 830 841.
13. Duda J. E., Giasson B. I., Mabon M. E., Lee V. M. Y. Trojanoswki J. Q. (2002) Novel antibodies to synuclein show abundant striatal pathology in Lewy body diseases. Ann. Neurol. 52, 205 210.
14. Forman M. S., Lee V. M. Trojanowski J. Q. (2005) Nosology of Parkinson's disease: looking for the way out of a quackmire. Neuron 47, 479 482.
15. Fornai F., Lenzi P., Gesi M. et al. (2004) Methamphetamine produces neuronal inclusions in the nigrostriatal system and in PC12 cells. J. Neurochem. 88, 114 123.
16. Fujiwara H., Hasegawa M., Dohmae N., Kawashima A., Masliah E., Goldberg M. S., Shen J., Takio K. Iwatsubo T. (2002) α-Synuclein is phosphorylated in synucleinopathy lesions. Nat. Cell Biol. 4, 160 164.
17. Garcia-Mata R., Bebok Z., Sorscher E. J. Sztul E. S. (1999) Characterization and dynamics of aggresome formation by a cytosolic GFP-chimera. J. Cell Biol. 146, 1239 1254.
18. Giasson B. I., Uryu K., Trojanowski J. Q. Lee V. M. Y. (1999) Mutant and wild type human alpha-synucleins assemble into elongated filaments with distinct morphologies in vitro. J. Biol. Chem. 274, 7619 7622.
19. Giasson B. I., Jakes R., Goedert M., Duda J. E., Leight S., Trojanowski J. Q. Lee V. M. Y. (2000) A panel of epitope-specific antibodies detects protein domains distributed throughout human alpha-synuclein in Lewy bodies of Parkinson's disease. J. Neurosci. Res. 59, 528 533.
20. Giasson B. I., Murray I. V. J., Trojanowski J. Q. Lee V. M. Y. (2001) A hydrophobic stretch of 12 amino acid residues in the middle of alpha-synuclein is essential for filament assembly. J. Biol. Chem. 276, 2380 2386.
21. Glenner G. G. (1980) Amyloid deposits and amyloidosis. N. Engl. J. Med. 302, 1283 1292.
22. Goedert M. (2001) Alpha-synuclein and neurodegenerative diseases. Nat. Rev. Neurosci. 2, 492 501.
23. Grant E. R., Bacskai B. J., Pleasure D. E., Pritchett D. B., Gallagher M. J., Kendrick S. J., Kricka L. J. Lynch D. R. (1997) N-Methyl-d-aspartate receptors expressed in a nonneuronal cell line mediate subunit-specific increases in free intracellular calcium. J. Biol. Chem. 272, 647 656.
24. Greenbaum E. A., Graves C. L., Mishizen-Eberz A. J., Lupoli M. A., Lynch D. R., Englander S. W., Axelsen P. H. Giasson B. I. (2005) The E46K mutation in alpha-synuclein increases amyloid fibril formation. J. Biol. Chem. 280, 7800 7807.
25. Hasegawa T., Matsuzaki M., Takeda A., Kikuchi A., Akita H., Perry G., Smith M. A. Itoyama Y. (2004) Accelerated alpha-synuclein aggregation after differentiation of SH-SY5Y neuroblastoma cells. Brain Res. 1013, 51 59.
26. Hashimoto M., Hsu L. J., Sisk A., Xia Y., Takeda A., Sundsmo M. Masliah E. (1998) Human recombinant NACP/alpha-synuclein is aggregated and fibrillated in vitro: relevance for Lewy body disease. Brain Res. 799, 301 306.
27. Johnston J. A., Ward C. L. Kopito R. R. (1998) Aggresomes: a cellular response to misfolded proteins. J. Cell Biol. 143, 1883 1898.
28. Kahle P. J., Neumann M., Ozmen L. et al. (2002) Hyperphosphorylation and insolubility of alpha-synuclein in transgenic mouse oligodendrocytes. EMBO Rep. 3, 583 588.
29. Klunk W. E., Pettegrew J. W. Abraham D. J. (1989) Quantitative evaluation of congo red binding to amyloid-like proteins with a beta-pleated sheet conformation. J. Histochem. Cytochem. 37, 1273 1281.
30. Koo H. J., Lee H. J. Im H. (2008) Sequence determinants regulating fibrillation of human alpha-synuclein. Biochem. Biophys. Res. Commun. 368, 772 778.
31. Koo H. J., Choi M. Y. Im H. (2009) Aggregation-defective alpha-synuclein mutants inhibit the fibrillation of Parkinson's disease-linked alpha-synuclein variants. Biochem. Biophys. Res. Commun. 386, 165 169.
32. Kordower J. H., Chu Y., Hauser R. A., Freeman T. B. Olanow C. W. (2008) Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's disease. Nat. Med. 14, 504 506.
33. Lee V. M. Trojanowski J. Q. (2006) Mechanisms of Parkinson's disease linked to pathological alpha-synuclein: new targets for drug discovery. Neuron 52, 33 38.
34. Lee H. J., Shin S. Y., Choi C., Lee Y. H. Lee S. J. (2002) Formation and removal of alpha-synuclein aggregates in cells exposed to mitochondrial inhibitors. J. Biol. Chem. 277, 5411 5417.
35. Lee G., Tanaka M., Park K., Lee S. S., Kim Y. M., Junn E., Lee S. H. Mouradian M. M. (2004) Casein kinase II-mediated phosphorylation regulates alpha-synuclein/synphilin-1 interaction and inclusion body formation. J. Biol. Chem. 279, 6834 6839.
36. Lee H. J., Patel S. Lee S. J. (2005) Intravesicular localization and exocytosis of alpha-synuclein and its aggregates. J. Neurosci. 25, 6016 6024.
37. Lee H. J., Suk J. E., Bae E. J., Lee J. H., Paik S. R. Lee S. J. (2008) Assembly-dependent endocytosis and clearance of extracellular alpha-synuclein. Int. J. Biochem. Cell Biol. 40, 1835 1849.
38. Li J. Y., Englund E., Holton J. L. et al. (2008) Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation. Nat. Med. 14, 501 503.
39. Lippa C. F., Schmidt M. L., Lee V. M. Trojanowski J. Q. (1999) Dementia with Lewy bodies. Neurology 52, 893.
40. Liu J., Zhang J. P., Shi M., Quinn T., Bradner J., Beyer R., Chen S. Zhang J. (2009) Rab11a and HSP90 regulate recycling of extracellular alpha-synuclein. J. Neurosci. 29, 1480 1485.
41. Luk K. C., Song C., O'Brien P., Stieber A., Branch J. R., Brunden K. R., Trojanowski J. Q. Lee V. M. (2009) Exogenous alpha-synuclein fibrils seed the formation of Lewy body-like intracellular inclusions in cultured cells. Proc. Natl Acad. Sci. U S A 106, 20051 20056.
42. Mazzulli J. R., Mishizen A. J., Giasson B. I., Lynch D. R., Thomas S. A., Nakashima A., Nagatsu T., Ota A. Ischiropoulos H. (2006) Cytosolic catechols inhibit alpha-synuclein aggregation and facilitate the formation of intracellular soluble oligomeric intermediates. J. Neurosci. 26, 10068 10078.
43. Murray I. V., Giasson B. I., Quinn S. M., Koppaka V., Axelsen P. H., Ischiropoulos H., Trojanowski J. Q. Lee V. M. (2003) Role of alpha-synuclein carboxy-terminus on fibril formation in vitro. Biochemistry 42, 8530 8540.
44. Nedelsky N. B., Todd P. K. Taylor J. P. (2008) Autophagy and the ubiquitin-proteasome system: collaborators in neuroprotection. Biochim. Biophys. Acta 1782, 691 699.
45. Neumann M., Kahle P. J., Giasson B. I. et al. (2002) Misfolded proteinase K-resistant hyperphosphorylated alpha-synuclein in aged transgenic mice with locomotor deterioration and in human alpha-synucleinopathies. J. Clin. Invest. 110, 1429 1439.
46. Nishie M., Mori F., Fujiwara H., Hasegawa M., Yoshimoto M., Iwatsubo T., Takahashi H. Wakabayashi K. (2004) Accumulation of phosphorylated alpha-synuclein in the brain and peripheral ganglia of patients with multiple system atrophy. Acta Neuropathol. (Berl) 107, 292 298.
47. O'Farrell C., Murphy D. D., Petrucelli L., Singleton A. B., Hussey J., Farrer M., Hardy J., Dickson D. W. Cookson M. R. (2001) Transfected synphilin-1 forms cytoplasmic inclusions in HEK293 cells. Mol. Brain Res. 97, 94 102.
48. Opazo F., Krenz A., Heermann S., Schulz J. B. Falkenburger B. H. (2008) Accumulation and clearance of alpha-synuclein aggregates demonstrated by time-lapse imaging. J. Neurochem. 106, 529 540.
49. Pandey N., Schmidt R. E. Galvin J. E. (2006) The alpha-synuclein mutation E46K promotes aggregation in cultured cells. Exp. Neurol. 197, 515 520.
50. Paxinou E., Chen Q., Weisse M., Giasson B. I., Norris E. H., Rueter S. M., Trojanowski J. Q., Lee V. M. Y. Ischiropoulos H. (2001) Induction of alpha-synuclein aggregation by intracellular nitrative insult. J. Neurosci. 21, 8053 8061.
51. Perrin R. J., Woods W. S., Clayton D. F. George J. M. (2000) Interaction of human alpha-synuclein and Parkinson's disease variants with phospholipids. Structural analysis using site-directed mutagenesis. J. Biol. Chem. 275, 34393 34398.
52. Polymeropoulos M. H., Lavedan C., Leroy E. et al. (1997) Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 276, 2045 2047.
53. Ren P. H., Lauckner J. E., Kachirskaia I., Heuser J. E., Melki R. Kopito R. R. (2009) Cytoplasmic penetration and persistent infection of mammalian cells by polyglutamine aggregates. Nat. Cell Biol. 11, 219 225.
54. Sampathu D. M., Giasson B. I., Pawlyk A. C., Trojanowski J. Q. Lee V. M. (2003) Ubiquitination of alpha-synuclein is not required for formation of pathological inclusions in alpha-synucleinopathies. Am. J. Pathol. 163, 91 100.
55. Sidhu A., Wersinger C. Vernier P. (2004) Does alpha-synuclein modulate dopaminergic synaptic content and tone at the synapse? FASEB J. 18, 637 647.
56. Smith W. W., Margolis R. L., Li X., Troncoso J. C., Lee M. K., Dawson V. L., Dawson T. M., Iwatsubo T. Ross C. A. (2005) Alpha-synuclein phosphorylation enhances eosinophilic cytoplasmic inclusion formation in SH-SY5Y cells. J. Neurosci. 25, 5544 5552.
57. Spillantini M. G., Schmidt M. L., Lee V. M. Y., Trojanowski J. Q., Jakes R. Goedert M. (1997) Alpha-synuclein in Lewy bodies. Nature 388, 839 840.
58. Spillantini M. G., Crowther R. A., Jakes R., Cairns N. J., Lantos P. L. Goedert M. (1998) Filamentous alpha-synuclein inclusions link multiple system atrophy with Parkinson's disease and dementia with Lewy bodies. Neurosci. Lett. 251, 205 208.
59. Tsuchiya K., Tajima H., Kuwae T. et al. (2005) Pro-apoptotic protein glyceraldehyde-3-phosphate dehydrogenase promotes the formation of Lewy body-like inclusions. Eur. J. Neurosci. 21, 317 326.
60. Tu P. H., Galvin J. E., Baba M. et al. (1998) Glial cytoplasmic inclusions in white matter oligodendrocytes of multiple system atrophy brains contain insoluble alpha-synuclein. Ann. Neurol. 44, 415 422.
61. Uversky V. N., Cooper M., Bower K. S., Li J. Fink A. L. (2002) Accelerated alpha-synuclein fibrillation in crowded milieu. FEBS Lett. 515, 99 103.
62. Waelter S., Boeddrich A., Lurz R., Scherzinger E., Lueder G., Lehrach H. Wanker E. E. (2001) Accumulation of mutant huntingtin fragments in aggresome-like inclusion bodies as a result of insufficient protein degradation. Mol. Biol. Cell 12, 1393 1407.
63. Waxman E. A. Giasson B. I. (2008) Specificity and regulation of casein kinase-mediated phosphorylation of alpha-synuclein. J. Neuropathol. Exp. Neurol. 67, 402 416.
64. Waxman E. A., Duda J. E. Giasson B. I. (2008) Characterization of antibodies that selectively detect alpha-synuclein in pathological inclusions. Acta Neuropathol. 116, 37 46.
65. Waxman E. A., Covy J. P., Bukh I., Li X., Dawson T. M. Giasson B. I. (2009a) Leucine-rich repeat kinase 2 expression leads to aggresome formation that is not associated with alpha-synuclein inclusions. J. Neuropathol. Exp. Neurol. 68, 785 796.
66. Waxman E. A., Mazzulli J. R. Giasson B. I. (2009b) Characterization of hydrophobic residue requirements for alpha-synuclein fibrillization. Biochemistry 48, 9427 9436.
67. Wood S. J., Wypych J., Steavenson S., Louis J. C., Citron M. Biere A. L. (1999) Alpha-synuclein fibrillogenesis is nucleation-dependent. Implications for the pathogenesis of Parkinson's disease. J. Biol. Chem. 274, 19509 19512.
68. Zhou W. Freed C. R. (2004) Tyrosine-to-cysteine modification of human alpha-synuclein enhances protein aggregation and cellular toxicity. J. Biol. Chem. 279, 10128 10135.
69. Zhou Z., Fan J. B., Zhu H. L. et al. (2009) Crowded, cell-like environment accelerates the nucleation step of amyloidogenic protein misfolding. J. Biol. Chem. 284, 30148 30158.
70. Zhuang Z. P., Kung M. P., Hou C., Skovronsky D. M., Gur T. L., Plossl K., Trojanowski J. Q., Lee V. M. Y. Kung H. F. (2001) Radioiodinated styrylbenzenes and thioflavins as probes for amyloid aggregates. J. Med. Chem. 44, 1905 1914.
71. Zibaee S., Jakes R., Fraser G., Serpell L. C., Crowther R. A. Goedert M. (2007) Sequence determinants for amyloid fibrillogenesis of human alpha-synuclein. J. Mol. Biol. 374, 454 464.